Literature DB >> 9173204

[Clinical value of somatostatin receptor scintigraphy. Studies of pre- and intraoperative localization of gastrointestinal and pancreatic tumors].

S Adams1, R P Baum, M Adams, H J Wenisch, P M Schumm-Draeger, A Encke, K H Usadel, G Hör.   

Abstract

BACKGROUND: [111In-DTPA-D-Phe1]-pentetreotide scintigraphy is able to detect neuroendocrine tumors not shown by radiological methods. PATIENTS AND METHODS: In 270 patients with neuroendocrine gastroenteropancreatic tumors (GEP tumors) 400 somatostatin receptor scintigraphies were performed. 70 patients (38 female, 32 male, aged 28 to 74 [56 +/- 12.6] years) underwent surgery and follow-up over 2 years. The aim of the present study was the comparison of preoperative somatostatin receptor scintigraphy with radiological methods (sonography, CT) and intraoperative localization of GEP tumors with a hand-held gamma-probe.
RESULTS: Somatostatin receptor scintigraphy was successful in localizing primary tumors in all patients. Liver- and lymph node metastases could be visualized with a sensitivity of 94 and 95 percent. In 7 patients 35 lesions could be identified by intraoperative tumor localization using a hand held gamma probe. Radiological methods identified only 11, surgical palpation 15 and preoperative somatostatin receptor scintigraphy 27 lesions.
CONCLUSION: Somatostatin receptor scintigraphy improves detection of small and occult GEP tumors. Intraoperative probe counting with a hand-held gamma probe can identify tumors even when they are small and impalpable, but receptor positive.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9173204     DOI: 10.1007/BF03043270

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  23 in total

1.  [Receptor scintigraphy in endocrine gastrointestinal and pancreatic tumors].

Authors:  K Joseph; J Stapp; J Reinecke; H Höffken; R Benning; C Neuhaus; M E Trautmann; W B Schwerk; R Arnold
Journal:  Dtsch Med Wochenschr       Date:  1992-06-26       Impact factor: 0.628

2.  Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.

Authors:  S W Lamberts; L J Hofland; P M van Koetsveld; J C Reubi; H A Bruining; W H Bakker; E P Krenning
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

3.  Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.

Authors:  E P Krenning; W H Bakker; W A Breeman; J W Koper; P P Kooij; L Ausema; J S Lameris; J C Reubi; S W Lamberts
Journal:  Lancet       Date:  1989-02-04       Impact factor: 79.321

4.  Somatostatin receptor imaging of endocrine gastrointestinal tumors.

Authors:  E P Krenning; D J Kwekkeboom; H Y Oei; J C Reubi; P M van Hagen; P P Kooij; A E Reijs; S W Lamberts
Journal:  Schweiz Med Wochenschr       Date:  1992-04-25

5.  Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe.

Authors:  W J Schirmer; T M O'Dorisio; T P Schirmer; C M Mojzisik; G H Hinkle; E W Martin
Journal:  Surgery       Date:  1993-10       Impact factor: 3.982

6.  [Localization of islet cell tumors using sonography, computed tomography, arteriography and selective transhepatic venous sampling for hormone assay (author's transl)].

Authors:  R Günther; F Kümmerle; J Beyer; K Klose; E P Kuhn; K Rückert; U Cordes
Journal:  Rofo       Date:  1981-12

7.  Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study.

Authors:  J A Norton; J L Doppman; R T Jensen
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

Review 8.  Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog.

Authors:  S W Lamberts; W H Bakker; J C Reubi; E P Krenning
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

9.  [Tc-99m-labeled anti-CEA antibodies in intraoperative diagnosis of colorectal cancer].

Authors:  P Lechner; P Lind; G Binter
Journal:  Nuklearmedizin       Date:  1995-02       Impact factor: 1.379

10.  [Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors].

Authors:  K Joseph; J Stapp; J Reinecke; H J Skamel; H Höffken; R Benning; C Neuhaus; H Lenze; M E Trautmann; R Arnold
Journal:  Nuklearmedizin       Date:  1993-12       Impact factor: 1.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.